Last checked at 15 Feb 2024 07:00
15 February 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
in-vitro siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further encouraging update on its ongoing in vitro siRNA research work.
The Company has now completed its in-vitro experiments combining EGFR (epidermal growth factor receptor) and PLK1 (Polo Like Kinase 1) siRNA molecules onto the same Nuvec® nanoparticle and testing it in PC9 lung cancer cells.
The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle.
Specifically, when cells were treated with the highest dose of 75nanomolars (nm) of single loaded EGFR siRNA, cell viability after 48 hours dropped to 38%. When cells were treated with 75nm of single loaded PLK1 siRNA cell viability dropped to 33%, yet when 75nm of EGFR and PLK1 were combined together cell viability dropped to 19%.
The cellular inhibition effect increases over time up to 48 hours and increases with the amount of siRNA applied. The experiments were carried out a number of times showing a consistent effect.
The Company will now expand this work by testing knockdown of EGFR alongside BRD4 (Bromodomain-containing-protein 4) and extend the EGFR/PLK1 data in a different cell line.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"The work we are doing on multiple loading of siRNA onto one nanoparticle is extremely encouraging and is showcasing the versatility of our Nuvec® delivery system.
"This ability to be able to knockdown two independent pathways leading to a positive added impact is an innovative approach in developing novel cancer treatments aimed at reducing the ability for tumour escape. We will continue to present this data to potential licensing partners as all this work strengthens the potential for collaboration opportunities."
For more information please contact:
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To hear more, visit |
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/NPwNAr | |
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
|
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen | Tel: +44(0)20 3934 6630 |
|
Glossary
siRNA: silencing RNA / short interfering RNA
EGFR: epidermal growth factor receptor, is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide.
Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis
Mitosis is the process by which a cell replicates its chromosomes and then separates them, producing two identical nuclei in preparation for cell division.
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre?clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.